Carrie C. Strom's most recent trade in Abbvie Inc was a trade of 2,876 Common Stock, $0.01 par value done at an average price of $146.4 . Disclosure was reported to the exchange on May 11, 2023.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| AbbVie | Carrie C. Strom | SVP & PRES GLOBAL ALLERG AESTH | Payment of exercise price or tax liability using portion of securities received from the company at price $ 146.42 per share. | 11 May 2023 | 2,876 | 28,024 (0%) | 0% | 146.4 | 421,104 | Common Stock, $0.01 par value |
| AbbVie | Carrie C. Strom | SVP & PRES GLOBAL ALLERG AESTH | Payment of exercise price or tax liability using portion of securities received from the company at price $ 156.06 per share. | 05 Mar 2023 | 449 | 30,900 (0%) | 0% | 156.1 | 70,071 | Common Stock, $0.01 par value |
| AbbVie | Carrie C. Strom | SVP & PRES GLOBAL ALLERG AESTH | Payment of exercise price or tax liability using portion of securities received from the company at price $ 154.28 per share. | 28 Feb 2023 | 5,762 | 32,159 (0%) | 0% | 154.3 | 888,961 | Common Stock, $0.01 par value |
| AbbVie | Carrie C. Strom | SVP & PRES GLOBAL ALLERG AESTH | Payment of exercise price or tax liability using portion of securities received from the company at price $ 155.27 per share. | 28 Feb 2023 | 810 | 31,349 (0%) | 0% | 155.3 | 125,769 | Common Stock, $0.01 par value |
| AbbVie | Carrie C. Strom | SVP & PRES GLOBAL ALLERG AESTH | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Feb 2023 | 16,205 | 16,205 | - | - | Option (Right to Buy) | |
| AbbVie | Carrie C. Strom | SVP & PRES GLOBAL ALLERG AESTH | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Feb 2023 | 7,809 | 0 | - | - | Option (Right to Buy) | |
| AbbVie | Carrie C. Strom | SVP & PRES GLOBAL ALLERG AESTH | Exercise or conversion of derivative security received from the company (such as an option) at price $ 56.93 per share. | 16 Feb 2023 | 7,809 | 60,092 (0%) | 0% | 56.9 | 444,566 | Common Stock, $0.01 par value |
| AbbVie | Carrie C. Strom | SVP & PRES GLOBAL ALLERG AESTH | Sale of securities on an exchange or to another person at price $ 151.28 per share. | 16 Feb 2023 | 7,780 | 53,067 (0%) | 0% | 151.3 | 1,176,958 | Common Stock, $0.01 par value |
| AbbVie | Carrie C. Strom | SVP & PRES GLOBAL ALLERG AESTH | Sale of securities on an exchange or to another person at price $ 151.29 per share. | 16 Feb 2023 | 7,646 | 38,888 (0%) | 0% | 151.3 | 1,156,763 | Common Stock, $0.01 par value |
| AbbVie | Carrie C. Strom | SVP & PRES GLOBAL ALLERG AESTH | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Feb 2023 | 6,546 | 47,209 (0%) | 0% | 0 | Common Stock, $0.01 par value | |
| AbbVie | Carrie C. Strom | SVP & PRES GLOBAL ALLERG AESTH | Sale of securities on an exchange or to another person at price $ 150.74 per share. | 16 Feb 2023 | 6,533 | 46,534 (0%) | 0% | 150.7 | 984,784 | Common Stock, $0.01 par value |
| AbbVie | Carrie C. Strom | SVP & PRES GLOBAL ALLERG AESTH | Exercise or conversion of derivative security received from the company (such as an option) at price $ 67.25 per share. | 16 Feb 2023 | 6,370 | 66,462 (0%) | 0% | 67.3 | 428,383 | Common Stock, $0.01 par value |
| AbbVie | Carrie C. Strom | SVP & PRES GLOBAL ALLERG AESTH | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Feb 2023 | 6,370 | 0 | - | - | Option (Right to Buy) | |
| AbbVie | Carrie C. Strom | SVP & PRES GLOBAL ALLERG AESTH | Sale of securities on an exchange or to another person at price $ 150.71 per share. | 16 Feb 2023 | 5,615 | 60,847 (0%) | 0% | 150.7 | 846,237 | Common Stock, $0.01 par value |
| AbbVie | Carrie C. Strom | SVP & PRES GLOBAL ALLERG AESTH | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Feb 2023 | 5,074 | 52,283 (0%) | 0% | 0 | Common Stock, $0.01 par value | |
| AbbVie | Carrie C. Strom | SVP & PRES GLOBAL ALLERG AESTH | Sale of securities on an exchange or to another person at price $ 150.78 per share. | 16 Feb 2023 | 567 | 38,321 (0%) | 0% | 150.8 | 85,492 | Common Stock, $0.01 par value |
| AbbVie | Carrie C. Strom | SVP & PRES GLOBAL ALLERG AESTH | Sale of securities on an exchange or to another person at price $ 151.34 per share. | 16 Feb 2023 | 400 | 37,921 (0%) | 0% | 151.3 | 60,536 | Common Stock, $0.01 par value |
| AbbVie | Carrie C. Strom | SVP & Pres Global Allerg Aesth | Payment of exercise price or tax liability using portion of securities received from the company at price $ 152.09 per share. | 11 May 2022 | 2,876 | 40,663 (0%) | 0% | 152.1 | 437,411 | Common Stock, $0.01 par value |
| AbbVie | Carrie C. Strom | SVP & Pres Global Allerg Aesth | Payment of exercise price or tax liability using portion of securities received from the company at price $ 152.83 per share. | 07 May 2022 | 234 | 43,539 (0%) | 0% | 152.8 | 35,762 | Common Stock, $0.01 par value |
| AbbVie | Carrie C. Strom | SVP & Pres Global Allerg Aesth | Payment of exercise price or tax liability using portion of securities received from the company at price $ 150.56 per share. | 05 Mar 2022 | 448 | 44,128 (0%) | 0% | 150.6 | 67,451 | Common Stock, $0.01 par value |
| AbbVie | Carrie C. Strom | SVP & Pres Global Allerg Aesth | Payment of exercise price or tax liability using portion of securities received from the company at price $ 150.56 per share. | 05 Mar 2022 | 355 | 43,773 (0%) | 0% | 150.6 | 53,449 | Common Stock, $0.01 par value |
| AbbVie | Carrie C. Strom | SVP & Pres Global Allerg Aesth | Payment of exercise price or tax liability using portion of securities received from the company at price $ 147.69 per share. | 02 Mar 2022 | 810 | 44,576 (0%) | 0% | 147.7 | 119,629 | Common Stock, $0.01 par value |
| AbbVie | Carrie C. Strom | SVP & Pres Global Allerg Aesth | Payment of exercise price or tax liability using portion of securities received from the company at price $ 149.54 per share. | 25 Feb 2022 | 2,840 | 45,386 (0%) | 0% | 149.5 | 424,694 | Common Stock, $0.01 par value |
| AbbVie | Carrie C. Strom | SVP & Pres Global Allerg Aesth | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Feb 2022 | 24,080 | 24,080 | - | - | Option(Right to Buy) | |
| AbbVie | Carrie C. Strom | SVP & Pres Global Allerg Aesth | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Feb 2022 | 5,727 | 48,226 (0%) | 0% | 0 | Common Stock, $0.01 par value | |
| AbbVie | Carrie C. Strom | SVP & Pres Global Allerg Aesth | Grant, award, or other acquisition of securities at price $ 47.27 per share. | 07 Feb 2022 | 4,184 | 44,895 (0%) | 0% | 47.3 | 197,778 | Common Stock, $0.01 par value |
| AbbVie | Carrie C. Strom | SVP & Pres Global Allerg Aesth | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Feb 2022 | 4,184 | 0 | - | - | Option (right to buy) | |
| AbbVie | Carrie C. Strom | SVP & Pres Global Allerg Aesth | Sale of securities on an exchange or to another person at price $ 141.17 per share. | 07 Feb 2022 | 2,396 | 42,499 (0%) | 0% | 141.2 | 338,243 | Common Stock, $0.01 par value |
| AbbVie | Carrie C. Strom | SVP & Pres Global Allerg Aesth | Sale of securities on an exchange or to another person at price $ 120.00 per share. | 23 Aug 2021 | 5,057 | 51,047 (0%) | 0% | 120 | 606,840 | Common Stock, $0.01 par value |
| AbbVie | Carrie C. Strom | SVP & Pres Global Allerg Aesth | Payment of exercise price or tax liability using portion of securities received from the company at price $ 116.22 per share. | 11 May 2021 | 2,887 | 56,104 (0%) | 0% | 116.2 | 335,527 | Common Stock, $0.01 par value |
| AbbVie | Carrie C. Strom | SVP & Pres Global Allerg Aesth | Payment of exercise price or tax liability using portion of securities received from the company at price $ 116.08 per share. | 07 May 2021 | 234 | 58,991 (0%) | 0% | 116.1 | 27,163 | Common Stock, $0.01 par value |
| AbbVie | Carrie C. Strom | SVP & Pres Global Allerg Aesth | Sale of securities on an exchange or to another person at price $ 112.40 per share. | 03 May 2021 | 4,184 | 59,225 (0%) | 0% | 112.4 | 470,282 | Common Stock, $0.01 par value |
| AbbVie | Carrie C. Strom | SVP & Pres Global Allerg Aesth | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 May 2021 | 4,184 | 0 | - | - | Option (right to buy) | |
| AbbVie | Carrie C. Strom | SVP & Pres Global Allerg Aesth | Exercise or conversion of derivative security received from the company (such as an option) at price $ 41.39 per share. | 03 May 2021 | 4,184 | 63,409 (0%) | 0% | 41.4 | 173,176 | Common Stock, $0.01 par value |
| AbbVie | Carrie C. Strom | SVP & Pres Global Allerg Aesth | Payment of exercise price or tax liability using portion of securities received from the company at price $ 105.65 per share. | 05 Mar 2021 | 448 | 59,704 (0%) | 0% | 105.6 | 47,331 | Common Stock, $0.01 par value |
| AbbVie | Carrie C. Strom | SVP & Pres Global Allerg Aesth | Payment of exercise price or tax liability using portion of securities received from the company at price $ 106.70 per share. | 05 Mar 2021 | 356 | 59,348 (0%) | 0% | 106.7 | 37,985 | Common Stock, $0.01 par value |
| AbbVie | Carrie C. Strom | SVP & Pres Global Allerg Aesth | Payment of exercise price or tax liability using portion of securities received from the company at price $ 106.70 per share. | 05 Mar 2021 | 123 | 59,225 (0%) | 0% | 106.7 | 13,124 | Common Stock, $0.01 par value |
| AbbVie | Carrie C. Strom | SVP & Pres Global Allerg Aesth | Payment of exercise price or tax liability using portion of securities received from the company at price $ 108.41 per share. | 02 Mar 2021 | 810 | 60,152 (0%) | 0% | 108.4 | 87,812 | Common Stock, $0.01 par value |
| AbbVie | Carrie C. Strom | SVP & Pres Global Allerg Aesth | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Feb 2021 | 32,298 | 32,298 | - | - | Option (right to buy) |